| Serial Number | 79389701 |
| Word Mark | RIBOCURE PHARMACEUTICALS AB |
| Filing Date | Friday, December 29, 2023 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Tuesday, January 21, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, February 11, 2025 |
| Description of Mark | The mark consists of the stylized wording "Ribocure" in black with the tittle over the letter "i" in orange and the letter "o" being formed by two curved vertical curves with the left curve in orange and the right curve in black, all over the stylized wording "Pharmaceuticals AB" in black, with all of the foregoing to the right of a stylized caduceus formed by a staff with a ball on top with one curving bar in black and a smaller waving ribbon over the bar in orange. |
| Goods and Services | medicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; biological preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for pharmaceutical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; medicinal preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating metabolic disorders; anticoagulants; cardiovascular pharmaceutical preparations; pharmaceutical preparations for ocular or intraocular surgery; depuratives for the body; veterinary preparations for the treatment and diagnosis of gastrointestinal diseases, cardiovascular diseases, metabolic diseases, and liver diseases; pesticides; medical dressings; composite materials for dental purposes; diapers for pets |
| Indication of Colors claimed | The color(s) orange and black is/are claimed as a feature of the mark. |
| NOT AVAILABLE | "PHARMACEUTICALS AB" |
| Goods and Services | technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research services; pharmaceutical research and development services; scientific research; chemical research and analysis; development and test of chemical production methods; biochemical research and analysis; development of pharmaceutical preparations and medicines; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, February 21, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, February 21, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Ribocure Pharmaceuticals AB |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 64 - NOT AVAILABLE |
| Address | SE |
| Event Date | Event Description |
| Thursday, February 15, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Wednesday, February 21, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, February 27, 2024 | APPLICATION FILING RECEIPT MAILED |
| Saturday, April 13, 2024 | NEW REPRESENTATIVE AT IB RECEIVED |
| Sunday, July 28, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, August 7, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, August 8, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Friday, August 16, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, August 16, 2024 | REFUSAL PROCESSED BY MPU |
| Friday, January 10, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, January 10, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, January 10, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, January 18, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Sunday, September 8, 2024 | REFUSAL PROCESSED BY IB |